

Clinical trials of antithrombotics for DVT prophylaxis in hip Fracture

TrialResults-center www.trialresultscenter.org

1 Low molecular weight heparin

| Trial | Treatments | Patients | Trials design and methods |
|--|---|----------------------|---------------------------|
| semuloparin vs enoxaparin | | | |
| SAVE-HIP 2 , 2012 [NCT00721760] n=500/503 follow-up: | Semuloparin 20 mg once-daily versus Enoxaparin 40 mg once-daily | hip fracture surgery | Parallel groups |
| dalteparin vs placebo | | | |
| Jorgensen , 1989 n=30/38 follow-up: 9 days | dalteparin 5000 x1 versus Placebo | Hip fracture | double blind |
| nadroparin vs placebo | | | |
| Sourmelis , 1995 n=72/78 follow-up: 10-12 days | nadroparin 3075x1 preop, 6150x1 post op versus Placebo | Hip fracture | double blind |
| certoparin + DHE vs Unfractionated heparin | | | |
| Lassen , 1989 n=68/71 follow-up: 6 days | certoparin 3000+0.5mg DHE x1 versus placebo | Hip fracture | double blind |

References

SAVE-HIP 2, 2012:

Lassen MR, Fisher W, Mouret P, Agnelli G, George D, Kakkar A, Mismetti P, Turpie AG Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE. J Thromb Haemost 2012 May;10:822-32 [22429800] [10.1111/j.1538-7836.2012.04701.x](https://doi.org/10.1111/j.1538-7836.2012.04701.x)

Jorgensen, 1989:

Sourmelis, 1995:

Lassen, 1989:

Lassen MR, Borris LC, Christiansen HM, Moller-Larsen F, Knudsen VE, Boris P, Nehen AM, Jurik AG, de Carvalho A, Nielsen BW Prevention of thromboembolism in hip-fracture patients. Comparison of low-dose heparin and low-molecular-weight heparin combined with dihydroergotamine. Arch Orthop Trauma Surg 1989;108:10-3 [2913977]

2 platelet aggregation inhibitors

| Trial | Treatments | Patients | Trials design and methods |
|---------------------------|------------|----------|---------------------------|
| aspirin vs placebo | | | |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|--|---|--|--|
| PEP hip-fracture , 2000 n=6679/6677 follow-up: 35 days | aspirin 160mg/d started preoperatively and continued for 35 days versus placebo | patients undergoing surgery for hip fracture | Parallel groups Double blind Australia, New Zealand, South Africa, |

References

PEP hip-fracture, 2000:

Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000 Apr 15;355:1295-302 [[10776741](#)]

3 synthetic oligosaccharide

| Trial | Treatments | Patients | Trials design and methods |
|---|--|--|---|
| fondaparinux vs enoxaparin | | | |
| PENTHIFRA (Eriksson) , 2001 n=831/840 follow-up: 11 days | fondaparinux 2.5-mg once-daily subcutaneous, starting 6 hours after surgery versus enoxaprin 40mg once daily | hip fracture surgery | Parallel groups double blind 21 countries |
| extended prophylaxis vs standard prophylaxis | | | |
| PENTHIFRAPLUS (Eriksson) , 2003 n=656 follow-up: 19-23 days | 25-31 days of fondaparinux 2.5-mg once-daily versus 6-8 days of fondaparinux 2.5-mg once-daily | patients undergoing hip fracture surgery | Parallel groups double blind |

References

PENTHIFRA (Eriksson), 2001:

Eriksson BI, Bauer KA, Lassen MR, Turpie AG Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001 Nov 1;345:1298-304 [[11794148](#)]

PENTHIFRAPLUS (Eriksson), 2003:

Eriksson BI, Lassen MR Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003 Jun 9;163:1337-42 [[12796070](#)]

4 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.